

February 27, 2015



## **HVCA honors David G. Watumull of Cardax as Life Science Entrepreneur of the Year**

HONOLULU, HI--The Hawaii Venture Capital Association honored David G. Watumull, CEO of Cardax, Inc. ("Cardax") (OTCQB:CDXI) as the 2014 Life Science Entrepreneur of the Year at its 15th annual awards gala at the Waialae Country Club on Thursday. Fostering entrepreneurial development through education and the venture community, the HVCA is the state of Hawaii's leading proponent of technology innovation. The award is given not only to represent accomplishments connected to the winner's own organization but to community service.

In presenting the award the HVCA said that Watumull's ability to keep his company's research and product development active during the most challenging economic environment since the Great Depression was a key factor.

The award also focused on some of the Company's most important achievements throughout the year:

- From May 2013 thru Feb 2014 Cardax raised \$10.8M in a series of financings leading to a reverse merge IPO in Feb 2014;
- The signing of an important collaboration deal with multi-national Pfizer spin-out and formulation expert Capsugel;
- The addition of three additional world-class pharmaceutical industry professionals to the Company's Board of Directors.

Mr. Watumull was also cited for his life science community mentoring work with other Hawaii-based life science companies.

Watumull said he was "pleased to receive the accolade" and said he had to give credit to the whole Cardax team, including employees, the Board, collaborators, and consultants.

### About Cardax

Cardax is a development stage life sciences company that devotes substantially all of its efforts to developing consumer health and pharmaceutical products that it believes provide many of the anti-inflammatory benefits of steroids or NSAIDS by targeting many of the same inflammatory pathways and mediators, but with exceptional safety profiles. Cardax is preparing proprietary nature-identical products and related derivatives by total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated, including, but not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease. The initial primary

focus of Cardax is its astaxanthin technologies. Astaxanthin is a powerful and safe naturally occurring anti-inflammatory and anti-oxidant without the adverse side effects typical of anti-inflammatory treatments using steroids or NSAIDS, including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding. The safety and efficacy of our product candidates have not been directly evaluated in clinical trials or confirmed by the FDA.

### Safe Harbor

This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

For additional information, please contact:

Janice Kam  
Cardax  
(808) 457-1400  
[press@cardaxpharma.com](mailto:press@cardaxpharma.com)